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Introduction: Inhaled corticosteroids (ICS) (in fixed combinations with long-
acting b2-agonists [LABAs]) are frequently prescribed for patients with chronic
obstructive pulmonary disease (COPD), outside their labeled indications
and recommended treatment strategies and guidelines, despite having the
potential to cause significant side effects.
Areas covered: Although the existence of asthma in patients with
asthma--COPD overlap syndrome (ACOS) clearly supports the use of anti-
inflammatory treatment (typically an ICS/LABA combination, as ICS monother-
apy is usually not indicated for COPD), the current level of ICS/LABA use is not
consistent with the prevalence of ACOS in the COPD population. Data have
recently become available showing the comparative efficacy of fixed bron-
chodilator combinations (long-acting muscarinic antagonist [LAMA]/LABA
with ICS/LABA combinations). Additionally, new information has emerged
on ICS withdrawal without increased risk of exacerbations, under cover of
effective bronchodilation.
Expert opinion: For patients with COPD who do not have ACOS, a LAMA/
LABA combination may be an appropriate starting therapy, apart from those
with mild disease who can be managed with a single long-acting bronchodi-
lator. Patients who remain symptomatic or present with exacerbations despite
effectively delivered LAMA/LABA treatment may require additional drug
therapy, such as ICS or phosphodiesterase-4 inhibitors. When prescribing an
ICS/LABA, the risk:benefit ratio should be considered in individual patients.
Keywords: chronic obstructive pulmonary disease, inhaled corticosteroid, long-acting
muscarinic antagonist, long-acting b2-agonist
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1. Introduction
Because chronic obstructive pulmonary disease (COPD) is viewed as an inflamma-
tory disease, inhaled corticosteroids (ICS) have come to be a widely used treatment.
Before the development of long-acting inhaled bronchodilators, ICS were pre-
scribed to patients with COPD. Following the Towards a Revolution in COPD
Health (TORCH) study, in which ICS monotherapy demonstrated an unfavorable
risk:benefit ratio [1,2], ICS are now generally administered in fixed combinations
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with long-acting b2-agonist (LABA) bronchodilators, and are
not recommended for use as monotherapy in COPD.
Although indicated for patients with repeated exacerbations
and/or severe airflow limitation, and in patients with asth-
ma--COPD overlap syndrome (ACOS), ICS-based treatments
are often used unnecessarily and contrary to recommenda-
tions, as well as their labeled indications [3-6]. Furthermore,
the benefits of these agents need to be weighed against the
risk of side effects, particularly pneumonia and diabetes [1,7-9].
In recent years, there has been increasing recognition of the
benefits of long-acting bronchodilators in a number of impor-
tant outcomes -- lung function, symptoms, health status and
exacerbations. This has led to the introduction of new agents
and fixed combinations of bronchodilators that provide
comparable efficacy to that of ICS/LABA, without the risk
of ICS-related side effects. ICS-related side effects reported
in patients with COPD include pneumonia [7,8,10,11],
increased bone fracture risk [12,13], skin bruising and delayed
healing [14], tuberculosis (in endemic areas) [15,16], diabetes [9],
cataracts [17,18], dysphonia and oropharyngeal candidiasis [1].
The risks of ICS have been fully reviewed elsewhere by
Price et al., 2013 [19] and Ernst et al., 2014 [20]. Patients
with COPD are likely to be more vulnerable to side effects
than those with asthma as they are older, more likely to
have received oral steroids (lifetime cumulative dose) and
the doses of ICS used in COPD are higher, especially in
Europe [19,21,22].
This review describes how ICS are currently overused and
how treatment with these agents is evolving, with newer
data illustrating the benefits of bronchodilators and
bronchodilator combinations and the possibility of reducing
or withdrawing ICS under cover of effective bronchodilation.
Where possible we will focus on the effect of treatment on
prevention of exacerbations, an important management goal
in COPD [4].
1.1 The use of ICS and ICS/LABA in COPD
The use of ICS in patients with COPD arose from the recog-
nition of the need for anti-inflammatory treatment in asthma
and the possibility that the inflammatory component of
COPD might be similarly amenable to such treatment [23].
However, the inflammatory processes of asthma and COPD
were shown to be fundamentally different [23], and some of
the early studies of ICS in patients with COPD demonstrated
no clinical benefit [24]. Other trials, whereas failing to show
any effect on the decline in lung function (as primary out-
come), revealed some benefit of ICS on health status and
exacerbations [25,26], the latter particularly in patients with
more severe disease and frequent exacerbations [27].
Patients with frequent exacerbations are more likely than
those with infrequent exacerbations to have eosinophilic
inflammation [28,29], and selection of such a population can
act as a potential source of bias. For this reason, care is needed
when extrapolating data from randomized controlled trials
with ICS. Other overt and hidden inclusion criteria that
have the potential to influence outcomes include existing
ICS users, who may be more prone than others to exacerba-
tions based on application of treatment strategies such as
GOLD [4], and specialist care patients, who are likely to
have a prior history of exacerbations. Additionally, adverse
consequences are more likely in patients with COPD with
high versus low co-morbidity.
The combined use of an ICS/LABA, which provides greater
improvement in lung function and symptom control than
doubling the ICS dose in asthma [30-32], has also been investi-
gated in COPD [33]. Many studies have since demonstrated
the efficacy of ICS/LABA combinations against placebo in
preventing exacerbations and improving lung function and
health status in patients with COPD [1,34,35]. Set against these
benefits, however, ICS are associated with significant and
potentially serious side effects.
2. ICS/LABA versus a single bronchodilator
2.1 ICS/LABA versus LABA
Most studies of ICS/LABA combinations have compared the
efficacy of the ICS/LABA versus the LABA monocomponent
(rather than a long-acting muscarinic antagonist [LAMA]). In
general, the ICS/LABA combination has demonstrated greater
efficacy in preventing exacerbations compared with the LABA
monocomponent, especially in more recent trials [1,7,36,37]. In
the early TRial of Inhaled STeroids ANd LABAs (TRISTAN)
study, there was no statistical difference in exacerbation rate
between an ICS/LABA (fluticasone/salmeterol combination
[FSC] 500/50 µg twice daily [b.i.d.]) and the LABA salmeterol
Article highlights.
. Inhaled corticosteroids (ICS; in fixed combinations with
long-acting b2-agonists [LABAs]) are often prescribed to
patients with COPD outside labeled indications and
recommended treatment strategies and guidelines,
despite the potential for side effects.
. Available data indicate that LABA/long-acting muscarinic
antagonist (LAMA) combination therapy provides
generally comparable efficacy to ICS/LABA treatment in
patients with stable COPD.
. ICS dose reduction or withdrawal under cover of
effective long-acting bronchodilator therapy does not
increase exacerbation rates in patients at low risk of
exacerbation.
. Two phenotypes are particularly relevant in determining
which patients should receive ICS: asthma--COPD
overlap syndrome (ACOS) and frequent exacerbators.
. A LAMA/LABA combination may be an appropriate
starting therapy for patients with COPD who do not
have ACOS, although patients with mild disease may be
managed with a single long-acting bronchodilator.
Additional drug therapy may be required for patients
who remain symptomatic or present with exacerbations
despite effectively delivered LAMA/LABA treatment.
This box summarizes key points contained in the article.
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alone [34]. In the 3-year TORCH study, FSC 500/50 µg b.i.d.
was more effective than salmeterol in preventing moderate
and severe exacerbations combined (rate ratio 0.88, i.e., 12%
reduction), but not severe exacerbations (rate ratio 1.02) [1].
Pneumonia was reported in 19.6% of the FSC group, 18.3%
of the fluticasone group, 13.3% of the salmeterol group and
12.3% of the placebo group. In a recently published study,
FSC 250/50 µg b.i.d. was no better than salmeterol alone in
preventing relapse during the 6 months after an admission
for an exacerbation of COPD, or for patient-reported health
outcomes [38].
In the 44-week VIVACE (Impact of Salmeterol/Flutica-
sone Propionate versus Salmeterol on Exacerbations in Severe
COPD) study, FSC 500/50 µg b.i.d. reduced moderate or
severe exacerbations by 35% compared with the LABA alone
in patients with severe disease and a history of frequent
exacerbations [7,28,29]. Exacerbation rates were also lower
with FSC 500/50 µg b.i.d. in patients with more severe forced
expiratory volume in 1 second [FEV1] (< 50% predicted)
versus mild-to-moderate disease (FEV1 > 50% predicted) at
baseline in the TRISTAN trial [34].
The ICS/LABA combination of budesonide/formoterol has
been shown to be more effective in preventing exacerbations
compared with formoterol alone [36,37]. In addition, some
have suggested that budesonide has less propensity to cause
pneumonia than fluticasone, which may have a higher, dose-
related risk [11,39,40]. However, the two drugs have not been
compared directly in randomized controlled trials, and diag-
nostic criteria for pneumonia can vary between studies.
The newer ICS/LABA formulation of fluticasone furoate
and vilanterol (100/25 µg once daily [q.d.]) significantly
reduced the rate of moderate and severe exacerbations com-
pared with vilanterol alone (p < 0.0001), an effect that was
driven mainly by a reduction in moderate exacerbations [41,42].
A significant reduction was also observed in a subgroup of
patients with frequent exacerbations (p = 0.0005). However,
an increased frequency of radiographically confirmed pneu-
monia was observed with the ICS/LABA (4% for the
100/25 µg q.d. dose approved for COPD) versus the LABA
alone (2%) [41,42].
In a population-based cohort study by Gershon et al. [43]
comparing new users of ICS/LABAs and LABAs, no signifi-
cant difference for the composite outcome of hospitalization
or death was observed between LABA/ICS and LABA alone
in the overall population. In a subgroup with coexistent
asthma, a significantly better outcome was observed with
LABA/ICS compared with LABA treatment. Rodrigo et al.
performed a systematic review of 18 randomized controlled
trials of ICS/LABA versus LABA and showed no significant
difference in relative risk for the number of severe exacerba-
tions or mortality (all-cause, respiratory or cardiovascular)
[44]. ICS/LABA treatment was associated with serious adverse
events (pneumonia) and the magnitude of their benefits (on
health status and moderate exacerbations) was regarded as
below the level of clinical importance. Small benefits on
lung function and health status were reported in a network
meta-analysis evaluating efficacy of an ICS/LABA versus a
LABA or LAMA [45]. It is important to note that pivotal land-
mark studies in COPD (such as Inhaled Steroids in Obstruc-
tive Lung Disease in Europe [ISOLDE] and TORCH),
whereas highlighting the merits of ICS and ICS/LABA treat-
ment, also revealed that many patients receiving these thera-
pies withdrew from study participation prematurely for
various reasons, including a lack of perceived benefit.
2.2 ICS/LABA versus LAMA
The comparative efficacy of ICS/LABAs versus LAMAs has
been less extensively investigated [46]. In the INSPIRE study
of patients with severe or very severe COPD, no difference
was observed between an ICS/LABA (FSC 500/50 µg b.i.d.)
and a LAMA (tiotropium) in reducing the risk of all exacerba-
tions, despite patients in the LAMA arm undergoing ICS
withdrawal to participate in the study [47]. Tiotropium was
more effective in preventing exacerbations requiring treat-
ment with antibiotics, whereas FSC was more effective for
exacerbations requiring systemic steroids. A Canadian study
reported by Aaron et al. [48] has also observed that addition
of an ICS/LABA (FSC 500/50 µg b.i.d.) to the LAMA
tiotropium did not improve COPD exacerbations rates
compared with LAMA monotherapy in patients with
moderate-to-severe disease. However, lung function, quality
of life and hospitalization rates were improved with triple
therapy versus LAMA treatment alone in this study (see also
further discussion of triple ICS/LAMA + LABA therapy
below). Subsequently, the authors of a 2013 Cochrane sys-
tematic review concluded that they were unable to determine
whether ICS/LABA or LAMA treatment had the lower mor-
tality rate based on the large INSPIRE trial and two smaller
studies comparing ICS/LABA with tiotropium [49]. Addition-
ally, it was not clear which therapeutic approach was better in
terms of reducing COPD exacerbations, hospitalizations
and serious adverse events or improving health status. This
conclusion was primarily due to missing outcome data for
patients who withdrew from INSPIRE and the resulting
possibility of bias in treatment effect.
3. ICS/LABA versus dual bronchodilation
Three fixed-dose LAMA/LABA combinations are currently
available: q.d. glycopyrronium/indacaterol 50/110 µg
(QVA149; Ultibro Breezhaler; Novartis) and umeclidinium/
vilanterol 62.5/25 µg (Laventair/Anoro Ellipta; Glaxo
SmithKline), and a b.i.d. combination of aclidinium/
formoterol 400/12 µg (Duaklir Genuair; AstraZeneca). Each
has been shown to be more effective in improving lung
function, compared with placebo or a single long-acting
bronchodilator alone [50-55]. A combination of tiotropium
and olodaterol, filed for approval in 2014, also improved
lung function relative to its monocomponents [56]. Although
all published LAMA/LABA studies have not shown consistent
A re-evaluation of the role of ICS in the management of patients with COPD
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significant improvement in other important outcomes (such
as dyspnea, moderate/severe exacerbations and clinically rele-
vant improvements in health status vs LAMA monotherapy),
overall trends are positive for the efficacy of LAMA/LABA
combinations as a class in these outcomes [57].
3.1 ICS/LABA versus LAMA/LABA
Before the fixed-dose LAMA/LABA combinations were devel-
oped, the concurrent administration of a LAMA (tiotropium)
and LABA (formoterol) using separate inhalers was shown to
improve lung function to a greater extent than FSC 500/50 µg
b.i.d. over 6 weeks of treatment in patients with moderate
COPD [58]. Similarly, Magnussen et al. reported a greater
effect on markers of hyperinflation in an 8-week study com-
paring the free combination of tiotropium and salmeterol
with FSC 500/50 µg b.i.d. [59]. Lending indirect support to
the use of combined bronchodilators, the large population-
based cohort study by Gershon et al. referred to earlier showed
no difference in primary outcome (hospitalization or death)
between new users of ICS/LABA and LABA when the latter
were also receiving a LAMA [43]. However, the possibility of
a type II error (false negative) cannot be excluded.
Current comparisons of fixed LAMA/LABA combinations
with ICS/LABA include two fully published studies compar-
ing QVA149 and FSC, and two abstracts comparing umecli-
dinium/vilanterol with FSC in three studies (Table 1). In the
ILLUMINATE study in symptomatic patients with COPD
and no moderate-to-severe exacerbations in the prior year,
q.d. QVA149 provided significant improvements in lung
function versus b.i.d. FSC 500/50 µg (p < 0.0001), with sig-
nificant improvement in dyspnea at 6 months (p = 0.0031)
[60]. In a post-hoc analysis of the ILLUMINATE data, there
was a 20% reduction in the rate of moderate or severe
exacerbations with QVA149 versus FSC, although this was
not significantly different [61].
In a similar population of symptomatic but stable patients
(no exacerbations in previous year), two 12-week studies com-
paring the umeclidinium/vilanterol 62.5/25 µg combination
and FSC (250/50 µg b.i.d.) reported improved lung function
with the LAMA/LABA and no difference between the two
treatments in dyspnea or health status [62-64]. Similar findings
were reported in a 12-week study comparing umeclidinium/
vilanterol 62.5/25 µg q.d. with FSC 500/50 µg b.i.d. [65].
The patient population in the 6-month LANTERN study
comparing QVA149 with FSC 500/50 µg b.i.d. included
patients with moderate-to-severe COPD and a history of up
to one exacerbation in the previous year. QVA149 demon-
strated better effects on lung function, similar effects on
patient-reported outcomes (dyspnea and health status) and
significantly reduced the rate of moderate or severe exacerba-
tions by 31% [66]. In the subgroup of patients with a history of
exacerbations (21% of total patients), the annualized rate of
all exacerbations was significantly lower with QVA149
(0.78) versus FSC (1.81), with a rate ratio of 0.43 (95% CI;
0.25, 0.76; p = 0.003). The annualized rate of moderate or
severe exacerbations was similar for each treatment among
patients with an exacerbation history (rate ratio 0.60, 95%
CI 0.33, 1.08; p = 0.086).
The studies comparing LAMA/LABA combinations with
an ICS/LABA have generally been conducted in non-
exacerbators, rather than in patients with a history of frequent
exacerbations for whom ICS would be appropriately pre-
scribed, and in whom ICS might be expected to be more
effective in preventing exacerbations [7]. The efficacy of a
LAMA/LABA versus an ICS/LABA on exacerbations in
patients with moderate-to-very-severe COPD and a history
of exacerbations is currently under investigation with
QVA149 in the 1-year FLAME study [67]. Another study, cur-
rently recruiting, will enable comparison of a LAMA/LABA
(umeclidinium/vilanterol) and an ICS/LABA (fluticasone
furoate/vilanterol 100/25 µg q.d.) over 1 year in patients
with a history of exacerbations [68].
4. Current use of ICS: the impact of dose
Many of the side effects of ICS, including pneumonia [11],
bone fracture risk [12], tuberculosis [15] and diabetes [9], are
dose-related, in terms of both daily dose and lifetime
exposure. Despite this, FSC is approved in the EU for use in
COPD only at a daily fluticasone propionate dose of
1000 µg, which is double the 500 µg daily dose approved for
COPD in the US and Japan. In their review of data on FSC
500/50 and 250/50 µg b.i.d. for use in COPD, the US FDA
reported both a higher frequency of adverse events (78 vs
70%) and no treatment benefit for the higher versus the lower
dose [69]. The dosage of budesonide in combination with the
LABA formoterol is also lower in the US than that approved
in the EU (200 and 400 µg b.i.d., respectively). Evidence to
support the use of the higher rather than the lower doses in
the EU is lacking [21,22]. Comparative efficacy data are also
lacking for other ICS agents, as a 2014 Cochrane network
meta-analysis identified only a few prospective head-to-head
trials evaluating different doses of the same ICS (administered
alone or with a LABA) on relevant COPD outcomes [45]. Addi-
tionally, the majority of studies powered to investigate the
effects of ICS on important COPD outcomes used a single
ICS dose that was the highest dose given among studies
included in the meta-analysis. Exceptions include trials of the
newer formulation of fluticasone, the furoate salt, which is
approved for COPD in the EU and the US at the same q.d.
dose of 100 µg (in combination with the LABA vilanterol),
after studies showed no additional benefit on lung function
or exacerbation frequency of a combination containing a
higher (200 µg) dose of fluticasone furoate [42]. Short-term
(12-week) head-to-head comparisons showed similar broncho-
dilator efficacy and also suggested a comparable incidence of
pneumonia between FSC 500/50 µg b.i.d. and fluticasone
furoate/vilanterol 100/25 µg q.d. [70]. In duplicate 1-year stud-
ies in patients with a history of exacerbations, the incidence of
pneumonia with fluticasone furoate/vilanterol 100/25 µg q.d.
A. D’Urzo et al.
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was higher than with vilanterol 25 µg q.d. alone (6 vs 3%) [42],
and similar to the incidence of 5% with FSC 500/50 µg b.i.d.
reported by Kardos et al. in a comparable patient
population [7].
Preparations of ICS of small particle size may offer the
prospect of similar efficacy at a reduced dose compared with
standard particle size ICS. Indeed, a recent observational
study reported comparable exacerbation rates over 2 years
when extrafine beclometasone was compared with a
1.2 -- 1.4-fold higher dose of fluticasone (relative doses were
calculated based on 1:1 equivalency) [71].
5. Which patients should receive ICS?
Some phenotypes are beginning to be identified among
patients with COPD and are an important consideration for
physicians when selecting treatment. This is acknowledged
in the Spanish guideline for COPD (GesEPOC) in which
diagnosis and management of COPD are based upon four
clinical phenotypes: a non-exacerbator phenotype; a mixed
COPD-asthma/ACOS phenotype; an exacerbator phenotype
with emphysema and an exacerbator phenotype with chronic
bronchitis (Figure 1) [72].
Two phenotypes are particularly relevant for physicians in
determining which patients should receive ICS: ACOS and
frequent exacerbators.
5.1 Asthma--COPD overlap syndrome
Some patients present with features of both COPD and
asthma, described as ACOS. As yet, there is no universally
accepted definition of ACOS and no validated diagnostic cri-
teria [73], although the GINA/GOLD collaboration provides a
clinical description: “ACOS is characterized by persistent air-
flow limitation with several features usually associated with
asthma and several features usually associated with COPD.
ACOS is therefore identified by the features that it shares
with both asthma and COPD”. The definition of ACOS
used in the COPDGENE study is similar and is increasingly
used: COPD based on usual spirometric criteria and a history
of smoking, plus history of asthma before the age of 40 years
[74]. The reported prevalence rates of ACOS have varied
widely, likely as a result of differences in definition, but
10 -- 20% of patients with COPD may have ACOS [73].
Although reliable biomarkers for ACOS are not currently
available, it is important to identify the syndrome due to
different therapeutic strategies for ACOS and COPD [4,73].
In patients with ACOS, the default is to start treatment as
for asthma, that is, an ICS at low or moderate dose plus a
LABA [4], in recognition of the potentially life-saving role of
ICS in asthma. LAMA treatment can also be considered in
addition to ICS/LABA. In the previously mentioned cohort
study by Gershon et al. comparing new users of ICS/LABA
or LABA, there was only a modest overall benefit for ICS/
LABA but the greatest difference was observed among
COPD patients with a co-diagnosis of asthma (difference of
-6.5% in the composite outcome of hospitalization or death
at 5 years), supporting the use of ICS in this population [43].
5.2 Patients with COPD who experience frequent
exacerbations
The frequent exacerbator phenotype is important, because it
is quite stable over time and is the strongest predictor of an
individual’s future risk of exacerbations [75]. Additionally, as
preventative treatments are available, identification of this
phenotype based on medical history is of paramount impor-
tance. ‘Frequent exacerbations’ is generally taken to mean at
least two exacerbations per year and defines a patient as high
risk in the GOLD assessment scheme (the definition may
Figure 1. Clinical phenotypes of COPD proposed by the Spanish guideline for COPD (Guıa Espan~ola de la EPOC; GesEPOC).
Reprinted from [72],  2014 with permission from Elsevier.
COPD: Chronic obstructive pulmonary disease.
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also be based on at least one hospitalization for exacerbation
per year) [4]. Initial treatment may be ICS-based, although
GOLD includes LAMAs as another preferred choice, and a
LAMA/LABA is an alternative option [4]. In the Spanish
phenotype-based approach, a bronchodilator would be the
initial choice with anti-inflammatory treatment employed if
exacerbations persist despite bronchodilation [72]. Recently,
the addition of roflumilast to ICS/LABA (with or without
background LAMA) treatment has been shown to further
reduce exacerbation rates and hospital admissions in patients
who also have chronic cough and sputum production,
compared with ICS/LABA or triple ICS/LAMA/LABA
therapy [76].
It has been reported that up to 70% of patients with
COPD are treated with high-dose ICS in many European
countries [21]. In practice, the burden of exacerbations does
not support such widespread use of ICS. Among 9219 patients
with diagnosed COPD in a UK primary care database, 28%
met the GOLD criteria for high-risk, frequent exacerba-
tors [77]. Similarly, a German real-life study of 6209 patients
reported that exacerbations were experienced by 28% of
patients over a 6-month period [78]. In the first year of
follow-up in the ECLIPSE cohort, frequent exacerbators
comprised only 22, 33 and 47% of those with moderate,
severe and very severe disease, respectively (using the GOLD
pre-2011 definitions of severity), with 7, 18 and 33% of these
groups hospitalized for an exacerbation [75]. There were no
exacerbations in 55% of patients with moderate disease,
41% of those with severe disease and in 29% of the very severe
group, in this cohort [75]. Thus, irrespective of the severity of
airflow limitation, the majority of all patients with COPD are
at low risk of exacerbations. Although this reinforces the tradi-
tional recommendation to prescribe ICS-based treatment
according to an individual’s exacerbation history, the ICS
withdrawal studies described below suggest that this issue is
more complex than previously thought.
5.3 Can ICS responders be identified pre-treatment?
Targeting ICS to those patients who are likely to respond
would minimize unnecessary exposure and costs while
increasing the chance of improved outcomes. Some of the
indicators of a probable ICS response in patients with
obstructive lung disease (such as a previous history of asthma,
atopy, positive bronchodilator test [reversibility], bronchial
hyperresponsiveness, high levels of the fraction of exhaled
nitric oxide and eosinophilia in sputum or blood) [28,79-86]
may reflect aspects of a COPD phenotype with eosinophilic
inflammation. For example, patients with a positive broncho-
dilator test have more bronchial eosinophilic inflammation
than those who are non-reversible [84]. A large bronchodilator
response (‡ 12% and ‡ 400 ml) may be required to predict
treatment response [20].
One study has reported that the frequency of exacerbations
and hospitalizations in patients with COPD was lower in a
group of patients who received ICS treatment based on their
level of sputum eosinophilia (anti-inflammatory treatment
was initiated or escalated if sputum eosinophils were > 3%,
and reduced or removed if sputum eosinophils were < 1%)
compared with those who received ICS treatment according
to traditional (British Thoracic Society) guidelines [87].
A post-hoc cluster analysis of clinical trial data with FSC
250/50 µg b.i.d. versus salmeterol alone identified three
groups of patients with different responses to FSC versus
salmeterol treatment, based on annual rates of moderate/
severe exacerbations. Patients with a positive bronchodilator
test (baseline bronchodilator reversibility ‡ 12%) and those
receiving diuretics had a greater reduction in exacerbations
with FSC versus salmeterol, whereas no significant difference
was seen between treatments in the third cluster without
bronchodilator reversibility who were not receiving diu-
retics [88]. The use of diuretics may have an effect on respira-
tory disease, or it may reflect the existence of cardiovascular
disease and the possibility of a generalized inflammatory state
that benefits from ICS. Recently, a post-hoc analysis of data
from two clinical trials stratified patients by baseline blood
eosinophil levels and compared the effect of fluticasone furo-
ate/vilanterol versus vilanterol alone on exacerbation rates [28].
Combination treatment was more effective than vilanterol in
patients with higher baseline levels of blood eosinophils
(29% reduction in exacerbations in those with blood
eosinophils ‡ 2% compared with a non-significant reduction
of 10% in those with eosinophils < 2%) [28]. These studies
excluded patients with a current diagnosis of asthma, but
did not exclude patients with eosinophilia or those with a
prior history of asthma, suggesting that undiagnosed ACOS
may have been present in some patients [42].
Blood or sputum eosinophilia during an exacerbation
have also been identified as biomarkers for a particular
(eosinophilia-associated) exacerbation phenotype [89], and
the usefulness of blood eosinophilia as a marker for directing
corticosteroid treatment of exacerbations has been
explored [86]. Sputum eosinophilia was identified as one of a
range of markers (along with longer duration of symptoms,
smoking history < 40 pack-years and ICS withdrawal in win-
ter months) predicting a higher risk of exacerbation following
ICS withdrawal [90]. A database study by Freeman et al.
reported that patients with frequent COPD exacerbations
and admissions could be predicted by female gender, asthma,
blood eosinophilia (‡ 450/µl) in non-smokers, nasal polyps
and COPD Assessment Test (CAT) score, suggesting the via-
bility of developing a risk assessment tool using variables typ-
ically included in primary care patient records [91].
Although blood eosinophil measurements may prove useful
for selecting patients for different therapeutic approaches, the
work is exploratory and a number of factors need to be inves-
tigated further before it can be validated. In the ECLIPSE
cohort, 37% of patients with COPD had blood eosinophil
counts persistently ‡ 2% (as did a similar proportion of
healthy control subjects) [92]. However, a single measurement
may not be adequate: in the ECLIPSE cohort, for example,
A. D’Urzo et al.
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blood eosinophils varied above and below the 2% cut-off over
the 3-year follow-up in 49% of patients [92]. The most appro-
priate cut-off is not known, nor whether it should be
expressed as a percentage or absolute number of cells.
6. ICS withdrawal to LAMAs, LABAs or
combination
Early studies showed that abrupt withdrawal of ICS under
cover of short-acting bronchodilators or theophylline alone
led to an increased risk of exacerbations compared with
continued ICS treatment [93-95]. This phenomenon may also
be a confounding factor in exacerbation studies when ICS
are given pre-treatment and then withdrawn at baseline [96,97].
However, recent studies in which patients were supported by
more effective bronchodilation have suggested ICS with-
drawal may not increase the risk of exacerbation, even in
patients with severe COPD.
In the 12-month WISDOM study, patients with severe
COPD and at least one exacerbation in the previous year
received tiotropium, salmeterol and fluticasone propionate
(500 µg b.i.d.) during a 6-week run-in and were randomized
either to continue this treatment or to step down the
fluticasone dose gradually and continue with tiotropium and
salmeterol alone [98]. The gradual withdrawal of ICS in
patients receiving LABAs and LAMAs did not result in an
increased risk of exacerbation. These patients had a clear
indication for ICS based on severe or very severe airflow lim-
itation (mean FEV1 34% predicted), but not necessarily based
on exacerbation history alone. The mean exacerbation
frequency in this population was around one per year.
Patients in the ICS-withdrawal group had small reductions
in FEV1 and health status during the stepped ICS withdrawal,
although the clinical importance of these changes is not
clear [99]. Interestingly, the lowest ICS dose in this study
(fluticasone propionate 100 µg b.i.d.) provided comparable
lung function to that observed with the 500 µg b.i.d. dose,
during a stepwise reduction in ICS dose and concurrent
LABA/LAMA treatment [98].
In the relatively small, real-life OPTIMO study, patients
with symptomatic COPD, moderate airflow limitation, fewer
than two exacerbations in the year prior to the study, and who
were receiving long-acting bronchodilators and ICS were
either continued on this treatment or maintained mostly on
long-acting bronchodilator(s) alone, at the discretion of the
treating physician [100]. The withdrawal of ICS was not
associated with any deterioration in symptoms, lung function
or exacerbation rate during 6 months of observation.
In the 26-week INSTEAD study, patients with moderate
COPD and no exacerbation in the past year, who had been
receiving FSC 500/50 µg b.i.d. for at least 3 months, were
either maintained on FSC or switched to a LABA alone
(indacaterol 150 µg q.d.) [101]. The two groups did not differ
in terms of lung function, symptoms, health status or exacer-
bation rate over the course of the study, and study
discontinuation rates were similar. As in the OPTIMO study,
this population of patients did not have an indication for ICS,
although such treatment reflects the common inappropriate
use of these agents [21].
It may also be noted that in the ILLUMINATE study com-
paring QVA149 and FSC in patients with stable COPD,
33% of patients in the QVA149 group had their previous
ICS treatment withdrawn at baseline [60]. During the run-in
following ICS withdrawal, the mean pre-bronchodilator
FEV1 decreased only by 35 ml or 1.8%. In these patients,
after 6 months, lung function was significantly better com-
pared with FSC (difference in FEV1 AUC0--12h 145 ml;
p < 0.0001) and they experienced no increase in the incidence
of exacerbations after withdrawal. Similarly, the decrease in
exacerbation risk with QVA149 versus FSC in the LAN-
TERN study (in which patients could have had a recent
exacerbation) was achieved despite the fact that 55% of the
QVA149-treated patients were on ICS that was withdrawn
at baseline [66].
7. Concluding remarks
Maintaining patients who are not frequent exacerbators on
ICS solely in an attempt to reduce exacerbation risk may
not be necessary, if they are also receiving effective bronchodi-
lator LAMA/LABA therapy. Newly diagnosed patients with
frequent exacerbations can be initiated on dual LAMA/
LABA therapy that may provide better bronchodilation, and
in many cases similar exacerbation protection, to an ICS/
LABA. Other preventative measures, as well as potential
contraindications for ICS, should also be considered. Despite
the recommended strategy for the use of ICS/LABA fixed
combinations and their approved indications, these agents
(whereas the mainstay of treatment for non-phenotypic
asthma) are greatly overused in COPD. There is growing
evidence that ICS treatment, if not indicated, can gradually
be withdrawn under cover of effective (LAMA/LABA) bron-
chodilation without increased exacerbation risk and with
only a very small decrease in FEV1. Low-dose ICS combina-
tion therapy based on US-approved dosages or data from
randomized controlled trials can also be considered.
The recent evidence of the relative efficacy and safety of a
LAMA/LABA versus an ICS/LABA suggests that a LAMA/
LABA combination could be first-line therapy in most
patients with COPD, the exceptions being the ‘mildest’
patients (who may need only one bronchodilator) and those
in whom ACOS is suspected. In the future, blood eosino-
philia testing could be a useful way of selecting those patients
who may benefit from ICS treatment, but this approach
requires further prospective clinical evaluation. Patients who
remain symptomatic or who present with exacerbations
despite LAMA/LABA treatment should receive additional
treatment, such as ICS or phosphodiesterase-4 inhibitors.
Another alternative might be the use of macrolides or muco-
lytics; however, no study has been conducted thus far with
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macrolides and mucolytics specifically on top of a LAMA/
LABA and further research is required.
8. Expert opinion
8.1 Where do ICS/LABA and LAMA/LABA
combinations fit in the treatment strategy?
ACOS is a special case in which the asthmatic element
presents airway inflammation that is amenable to intervention
with ICS, and these patients should receive first-line ICS-
based therapy in accordance with recommendations for
asthma treatment [4,72]. In patients with COPD only, there
is evidence to support the use of an ICS-based regimen (i.e.,
ICS/LABA) for patients with a history of repeated exacerba-
tions, who have significant symptoms despite regular therapy
with long-acting bronchodilators, in line with the EU indica-
tions for ICS/LABA (Table 2). However, an approach of
‘lowest effective dose’ may be preferable over the high
EU-approved doses of fluticasone propionate or budeso-
nide [22]. For patients with frequent exacerbations, the
Spanish guideline recommends a stepwise approach, starting
with a single bronchodilator and progressing with increasing
severity to the addition of an anti-inflammatory agent and/
or second bronchodilator [72].
In the GOLD strategy, in which treatment is based on risk
rather than phenotypes, ICS/LABA is a recommended first-
choice treatment for high-risk patients (groups C and D),
risk being determined by frequency of exacerbations and/or
airflow limitation [4]. However, lung function is a relatively
poor predictor of exacerbation risk [91], and most patients in
groups C and D are classified as such on the basis of low air-
flow limitation only (70 -- 78% in group C; 63 -- 79% in
group D), rather than frequent exacerbations (9 -- 23%) or
both (2 -- 28%; Figure 2). Similarly, in a survey of patients
in UK general practice, 70% of 2282 patients with severe air-
flow limitation had a low exacerbation risk profile
(£ 1 exacerbation) [102]. Subdivision of the GOLD groups C
and D may be warranted in order to target ICS-based treat-
ment more precisely to the appropriate frequent exacerbator
Table 2. Approved COPD indications in the EU and US for some LABA/ICS combinations.
Drug Daily dose Indication
EU US
Fluticasone
propionate/
salmeterol
500/50 µg  2 Symptomatic treatment of patients with COPD, with a
FEV1 < 60% predicted normal (pre-bronchodilator) and
a history of repeated exacerbations, who have
significant symptoms despite regular bronchodilator
therapy
Not approved
Fluticasone
propionate/
salmeterol
250/50 µg  2 Not approved Twice-daily maintenance treatment of
airflow obstruction in patients with COPD,
including chronic bronchitis and/or
emphysema
Also indicated to reduce exacerbations of
COPD in patients with a history of
exacerbations
Budesonide/
formoterol
400/12 µg  2 Symptomatic treatment of patients with severe COPD
(FEV1 < 50% predicted normal) and a history of
repeated exacerbations, who have significant symptoms
despite regular therapy with long-acting bronchodilators
Not approved
Budesonide/
formoterol
200/6 µg  2 Not approved Maintenance treatment of airflow
obstruction in patients with COPD
including chronic bronchitis and
emphysema
Fluticasone
furoate/
vilanterol
100/25 µg Symptomatic treatment of adults with COPD with a
FEV1 < 70% predicted normal (post-bronchodilator)
with an exacerbation history despite regular
bronchodilator therapy
Long-term, once-daily, maintenance
treatment of airflow obstruction in
patients with COPD, including chronic
bronchitis and/or emphysema
Also indicated to reduce exacerbations of
COPD in patients with a history of
exacerbations
COPD: Chronic obstructive pulmonary disease; FEV1: Forced expiratory volume in 1 second; LABA: Long-acting b2-agonist; LAMA: Long-acting muscarinic
antagonist; ICS: Inhaled corticosteroids.
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phenotype, in accordance with the current EU labels of the
ICS/LABA combinations (Table 2).
Another difficulty is in the case of patients with concomi-
tant bronchiectasis who are unlikely to benefit from ICS.
Bronchiectasis is present in up to approximately half of the
patients with severe COPD, and is associated with severe air-
flow limitation, severe exacerbations and chronic bacterial
colonization [103-105].
8.2 ICS withdrawal: unanswered questions
Although ICS withdrawal under cover of effective bronchodi-
lation appears to be a realistic possibility for patients at low
risk of exacerbation, several questions remain unanswered.
In the studies described in the previous section, ICS were
withdrawn during either single or dual long-acting broncho-
dilator treatment. There are currently no guideline recom-
mendations for ICS withdrawal, but the clinician would
need to judge what constitutes effective bronchodilation for
an individual patient, either a single long-acting bronchodila-
tor or, probably more likely, a dual LAMA/LABA. For
patients at low risk of exacerbation receiving a high EU-
approved ICS dose plus a LABA, gradual ICS withdrawal
under dual bronchodilation could be considered.
The interplay between lung function and exacerbation risk
requires further study, and many patients who meet GOLD C
and D criteria are not necessarily exacerbators. With the
exception of the WISDOM trial in patients with severe-to-
very severe airflow limitation [98], the ICS withdrawal studies
described previously were conducted in patients with COPD
who did not have a clear indication for ICS [100,101]. The
WISDOM trial included patients with at least one
exacerbation [98], but ICS withdrawal in a specific population
of frequent exacerbators (defined as at least two exacerbations
per year) has not been explored. In frequent exacerbators, the
dose of ICS may be reduced, but these agents should not be
completely withdrawn except where contraindicated (for
example, due to pneumonia, bronchiectasis or candidiasis),
until broadly accepted biomarker or phenotype characteriza-
tions that identify patients who will benefit from ICS treat-
ment are available. Withdrawal of ICS might be a potential
consideration in a patient who suffers an episode of pneumo-
nia, even if there is a history of frequent exacerbations. Dual
LAMA/LABA treatment, roflumilast if indicated, and/or
long-term macrolides, as well as vaccinations and other pre-
ventative measures should be offered in this context. As dis-
cussed above, an alternative strategy would be to initiate
treatment with a LAMA/LABA and add or subtract further
treatment as the patient’s condition requires.
Until recently, most ICS studies have looked at mean treat-
ment effects across patient populations. This approach may
mix results in different patient subgroups (such as previous
ICS users and ICS-naive patients) and show a treatment effect
in the overall population that is only present in one sub-
group [97]. Future studies are needed that look at interactions
between patient baseline characteristics and response to
therapy a priori.
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